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INTRODUCTION
Mature B-cell neoplasms, which are clonal proliferations
of B cells at various stages of differentiation, comprise over
90% of lymphoid neoplasms in western countries and about
75% of non-Hodgkin’s lymphomas (NHLs) in Korea (1-3).
The distinctive morphology and immunophenotypes of
mature B-cell neoplasms allow them to be readily classified
by postulated cell of origin. Among many types of mature
B-cell lymphoma, B-cell chronic lymphocytic leukemia (CLL)
and mantle cell lymphoma (MCL) typically contain CD5
positive B cells, which can be observed within the period
from naive B-cell to mantle cell. Recently, in addition to
the two well-known lymphomas, another type of lymphoma
with CD5 antigen expression has been reported in Japan (4,
5). This type lymphoma, so-called CD5 positive diffuse
large B cell lymphoma (CD5+ DLBCL), was first described
in western country, and has received much attention lately
because it has been suggested to possess more aggressive clin-
ical features and a poor outcome (6). Thus attempts have
been made to categorize CD5+ DLBCL as new disease enti-
ty, distinct from CD5- DLBCL, CLL or MCL (7-9). The iden-
tification of a high-risk subgroup of DLBCL would be partic-
ularly important for determining therapeutic strategy, given
that treatment is successful in only 35 to 40% of DLBCL
patients (10). Therefore, we investigated DLBCL cases in all
CD5 positive lymphoid malignancies with bone marrow
involvement, as proven by flow cytometry, and also examined
the clinical data, the histo-morphology, and immunopheno-
typing and cytogenetic result in these cases.
MATERIALS AND METHODS
We searched for CD5 positive cases of B-cell lymphoid
malignancy involving the bone marrow among patients admit-
ted to the Samsung Medical Center between 1997 and 2003.
CD5 expression was confirmed by immunophenotyping using
flow cytometry, which was performed using the following
panel of lymphoid cell associated monoclonal antibodies: anti-
CD2, CD3, CD5, CD7, CD10, CD19, CD20, CD23, FMC7,
and surface immunoglobulin (Ig) (Becton Dickinson, CA,
U.S.A.). The analyzed cells were gated on FSC/SSC and reveal-
ed lymphoid light scatter and moderate CD45 expression.
Twenty-five cases of B-cell lymphoid malignancies showed
CD5 expression; corresponding medical records were reviewed.
Bone marrow histomorphologies of the 25 cases were re-eval-
uated using Giemsa and hematoxylin-eosin stains by three
different pathologists. Diagnosis was based on the criteria
documented in the REAL/WHO classification (11). In brief,
CLL was defined as a case showing monomorphic small lym-
phocytes with CD5 and CD23 expression, and mantle cell
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De novo CD5 Positive Diffuse Large B-cell Lymphomas with Bone
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In CD5 positive (CD5+) mature B-cell lymphomas, newly recognized CD5+ diffuse
large B-cell lymphoma (DLBCL) has been characterized by aggressive features.
We studied twenty-five cases with CD5+ lymphomas involving bone marrow. Eleven
cases were diagnosed as chronic lymphocytic leukemia, six cases were diagnosed
as mantle cell lymphoma (MCL), and three cases with morphologic characteristics
of MCL and without both the cyclin D1 expression and IGH/CCND1 rearrangement
were unclassifiable. The remaining five cases, showing large to medium-sized lym-
phoid cells with prominent nucleoli and a moderate amount of cytoplasm, were diag-
nosed as DLBCL. Five DLBCL cases were positive for CD5, CD20, surface immuno-
globulin, but negative for CD23. Patients with CD5+ DLBCL showed a high age of
onset (median, 68 yr) and two patients expired one month after the diagnosis. Since
CD5+ DLBCL forms a distinct subgroup of DLBCL, a study of CD5 expression in
DLBCL would be helpful to predict prognosis and to determine future therapeutic
strategy. To the best of our knowledge, this is the first report on de novo CD5+ DLBCL
in Koreans.
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lymphoma was restricted to cases with cyclin D1 expression
by immunohistochemistry (Novocastra, CA, U.S.A.) in either
a lymph node or bone marrow. Cytogenetic analysis was per-
formed as follows: unstimulated bone marrow cells were cul-
tured for 24 hr and G-banded, and twenty metaphase cells
were analyzed and karyotyped, according to the guidelines
of the International System for Cytogenetic Nomenclature
(ISCN) 1995 (12). Dual color FISH with IGH/CCND1 probes
was undertaken according to the manufacturer’s instructions
(Vysis Inc., Downers Grove, IL, U.S.A.), and 200 nuclei from
interphase cells were analyzed. To determine the reference
range of IGH/CCND1 FISH, 200 nuclei from 20 normal
bone marrow specimens were observed; no true positive fusion
signals (1G2O1F) were observed.
RESULTS
Among the 25 cases of B-cell lymphoid malignancies show-
ing CD5 expression, 11 cases showed small sized lymphoid
cells with clumped chromatin and scant cytoplasm express-
ing CD5 and CD23. These cases were diagnosed as B-CLL
(Table 1). Another 9 cases showed small to medium sized
cells with the characteristics of mantle cells; these were CD5+
and CD23-. Among these 9 cases, six expressed cyclin D1
by immunohistochemistry, but only two cases revealed the
IGH/CCND1 rearrangement by FISH, and the remaining
three cases showed neither cyclin D1 expression nor the IGH/
CCND1 rearrangement. We finally diagnosed six cases show-
ing cyclin D1 expression as MCL; the other three cases were
unclassifiable. Finally, the remaining five cases showed medi-
um to large-sized lymphoid cells with prominent nucleoli
and a moderate amount of cytoplasm. Immunophenotypi-
cally they were positive for CD5, CD19, CD20 and surface
Ig  or  , and negative for CD23 and CD10 (Fig. 1 and 2).
All five cases were confirmed to be cyclin D1 negative, and
a FISH study identified no case with the IGH/CCND rear-
rangement. After considering morphology, immunopheno-
type, immunohistochemistry, and FISH results, we ruled out
CLL and MCL, and diagnosed the five cases as centroblastic
type DLBCL with CD5+.
The characteristics of CD5+ DLBCL cases at presentation
Morphology No. of cases
CD5/CD23 in
flow cytometry
Cyclin D1/
IGH/CCND1 
rearrangement*
B-CLL 11 Small lymphocytes with clumped chromatin and scant cytoplasm +/+ -/-
MCL 6 Small to medium sized cells with irregular nuclear contour and slightly  -/+ +/±
dispersed chromatin
CD5+ DLBCL 5 Medium to large sized cells with distinct nucleoli and  +/-- /-
a moderate amount cytoplasm
Unclassified  3 Small to medium sized cells with irregular nuclear contour  +/-- /-
and slightly dispersed chromatin
Table 1. The key features of CD5 positive mature B-cell lymphomas in the present study
B-CLL, B-cell chronic lymphocytic leukemia; MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma.
*Cyclin D1 expression was studied by immunohistochemistry and the IGH/CCND1 rearrangment was determined by dual color FISH with IGH/CCND1
probes (Vysis Inc., IL, USA).
Case
Age (yr)/
Sex
Initial site of 
involvement 
WBC 
(×10
9/L) 
Tumor cells 
(PB/BM%) 
CD5/
20 (%) Chromosome
Survival
Months
1 53/M BM, Liver, Spleen, LN 97.9 76/36 96/95 47,XY,del(4)(p15.2),-7,add(7)(p22),add(9)(p24), 1
del(9)(p13),+18,+mar[14]/46,XY[6]
2 65/M BM, Liver, Spleen 4.4 0/31 33/33 47-48,X,-Y,dup(1)(q21q25),t(1;4)(q42;q31), 1
t(1;5)(p13;q13),del(7)(p13),t(8;9)(q13;q22),
+12,add(14)(q32),+2mar[cp16]/46,XY[3]
3 65/M BM, LN 47.5 75/76 50/85 No mitotic cells 1*
4 70/F BM, LN 11.4 70/52 73/91 47,XX,+6,t(9;16)(p22;q24),inv(11)(p15q23), 60*
add(14)(q32),add(18)(q23)[2]/47,XX,idem,
t(8;12)(q24.3;q24.1)[10]/46,XX[8]
5 79/F BM, Liver, Spleen,  12.9 20/49 89/89 46~48,der(1)add(1)(p13)dup(1)(q12q32)add(1)(q32), 3*
LN, Pleural effusion der(1)add(1)(p36.3)dup(1)add(1)(q32),+der(3)r(3;?)(p21;?),
+der(3)t(3;?)(p21;?),-8,add(13)(q32),15,add(17)(p13),
-del(17)(p11.2),+18,add(21)(p11.2)[cp15]/46,XX[5]
Table 2. Clinical and laboratory findings of patients with de novo CD5+ DLBCL
*, Alive. CD5+ DLBCL, CD5 positive diffuse large B-cell lymphoma; BM, bone marrow; LN, lymph node.De novo CD5 Positive DLBCL 817
are summarized in Table 2. They showed a high age of onset
(median, 68 yr), and no case had a history of low-grade lym-
phoma. Thus, they were categorized as de novo CD5+ DL-
BCL. They all received chemotherapy with the CHOP regi-
men (cyclophosphamide, doxorubicin, vincristine, and pred-
nisone) and two patients (cases 1 and 2) expired one month
after initial diagnosis. 
DISCUSSION
The undefined three cases showing mantle cell morphology
without cyclin D1expression and IGH/CCND1 rearrange-
ment, which required further study including DNA microar-
ray analysis, to define a diagnostic category. The presence of
these cases implies that the REAL/WHO classification is not
sufficient to classify diverse mature B-cell lymphoid malig-
nancies. Recently, clusters of cases between typical CLL and
MCL were reported based on flow cytometry, and they were
found to be correlated with prognosis (13). Thus, an additional
study should contribute to our understanding of mature B-
cell lymphoid malignancies.
CD5+ cases account for approximately 5-10% of DLBCL,
and usually the frequency of infiltration of bone marrow, the
most frequent site of extranodal involvement, is reported to
be around 25% (4, 5). In the present study, the frequency of
CD5+ DLBCL among the 25 cases of CD5 positive B-cell
lymphoid malignancies involving the bone marrow was 24%,
which is not an insignificant number. In view of the fact that
reports of CD5+ DLBCL are rare in Korea, a serious under-
estimation of CD5+ DLBCL is suspected.
De novo CD5+ DLBCL has been recognized to have dis-
tinct features; a high age at onset, a female preponderance, a
frequent association with poor prognostic components, and
an aggressive clinical course (5). Our cases also showed a higher
average age of onset than general DLBCL in Korea (2) and
frequent extranodal infiltration of both liver and spleen. 
To explain the correlation between CD5 expression and an
unfavorable prognosis, genetic aberrations of CD5+ DLBCL
have been evaluated in a number of ways. Initially, an inves-
tigation targeting D13S25, p16, and p53 was performed,
and the deletion at the D13S25 locus and loss of p16 were
revealed, which implies an early transforming event resulting
in aggressive DLBCL (8). In addition to the above mentioned
genetic aberrations, the expressions of several other markers
such as BCL2, cyclin D3, cyclin B, or survivin have been pro-
posed to be associated with poor outcome (10). Following a
DNA microarray analysis, it was reported that the outcome
A B
Fig. 1. The morphologic findings of a case with CD5+ diffuse large B-cell lymphomas. Medium sized cells with moderately condensed cleaved
nuclei with distinct nucleoli, and a moderate amount of cytoplasm are observed. (A) Bone marrow aspirate, ×1,000, Wright-Giemsa stain,
(B) Bone marrow biopsy, ×400 Hematoxylin-Eosin stain.
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Fig. 2. Immunophenotyping of malignant lymphoid cells of CD5
positive diffuse large B-cell lymphomas shows CD5+CD10-CD
19+CD20+CD23- phenotype. (A) CD45/SSC (B) CD5/20 (C) CD
10/19 (D) CD3/23, Note the gated areas, black head arrowed. 
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of patients with DLBCL might be influenced by gene expres-
sion profiles other than histologic profiles (14), and that the
gene signature is associated with the control of cell kinetics
and host immune response (15). Thus, study of the genetic
aberrations of CD5+ DLBCL would help elucidate previously
indistinct diagnostic categories. 
The aggressive behavior of CD5+ DLBCL has also been
attributed to a tendency to spread widely within tissue, and
this phenomenon was associated with the CD5 molecule inter-
acting as a ligand with heavy-chain variable framework re-
gions of surface Ig (16). The latest study on this topic revealed
that the aggressiveness of CD5+ DLBCL might be due to the
overexpression of integrin  1 and/or CD36 adhesion mole-
cules (17). Integrin  1, an adhesion molecule, plays an impor-
tant role in B-cell lymphoma adhesion and chemotaxis on fibro-
nectin (18). The protein expression of integrin  1 has already
been reported to be associated with extranodal involvement in
NHL (19). The CD36 antigen is transcriptionally regulated
by Oct-2, which is a regulator of B-cell differentiation, and its
expression is reported to be an indicator of tumor metastasis
(20, 21). However, CD36 in CD5+ DLBCL tissues is express-
ed in the vascular endothelial cells rather than in malignant
cells. This finding implies the pathophysiologic role of the
vascular endothelium as an integral part of the cancer, and
would explain the high frequency of intravascular or intra-
sinusoidal infiltration observed in de novo CD5+ DLBCL (5). 
In conclusion, the present study found that de novo CD5+
DLBCL, with its distinct clinicopathologic features, is present
in Korea. Moreover, the characteristics of our CD5+ DLBCL
cases share many similarities with those previously reported.
Since CD5+ DLBCL may form a distinct subgroup of DLB-
CLs, there is a need to determine the presence or absence of
CD5 antigen expression in all DLBCL cases. It is thus essen-
tial to study CD5 expression in DLBCL by immunohisto-
chemistry or flow cytometry, as such findings would be help-
ful for to predict prognosis and determine future therapeutic
strategy. In addition, cytogenetic studies and molecular anal-
yses for proto-oncogenes and tumor suppressor genes would
provide insights into the pathogenesis of CD5+ DLBCL, and
provide information relevant to the establishment of innova-
tive therapeutic strategies. Furthermore, regarding the diffi-
culty in making a diagnosis of heterogeneous mature B-cell
lymphomas, comprehensive flow cytometry, cytogenetic and
molecular genetic study would aid in the diagnosis of all
mature B cell lymphoid malignancies. 
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